Ovarian Clear Cell Adenocarcinoma Review (OCCA)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02129036 |
Recruitment Status :
Completed
First Posted : May 2, 2014
Last Update Posted : August 9, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Ovarian Cysts |
- Several authors have reported frequent admixtures of clear cell ovarian carcinoma with serous, mucinous, and endometrioid tumors. However, few papers addressed the difference in response to chemotherapy and survival between patients with pure and mixed-type advanced clear cell carcinoma.
- Recent trends in the clinical management of advanced ovarian cancer include increased attention to maximal cytoreduction and general acceptance of paclitaxel-platinum-based adjuvant chemotherapy.
- The introduction of paclitaxel markedly changed the postoperative management of ovarian cancer patients, but the results and value of these newer efforts and therapies applied to clear cell carcinoma are as yet undetermined.
- Today, paclitaxel-platinum-based chemotherapy is becoming the standard regimen for ovarian cancer worldwide. Previous research suggests a potential benefit of paclitaxel plus carboplatin regimens for stage I clear cell carcinoma. However, few papers specifically addressed the efficacy of paclitaxel-platinum-based chemotherapy for advanced clear cell carcinoma because clear cell carcinoma occurs only rarely in Western countries.
Study Type : | Observational |
Actual Enrollment : | 5 participants |
Observational Model: | Case-Only |
Time Perspective: | Retrospective |
Official Title: | Retrospective Multi-institutional Survey of Clinical Characteristics in Ovarian Clear Cell Adenocarcinoma Cancer Patients |
Study Start Date : | April 2008 |
Actual Primary Completion Date : | December 2012 |
Actual Study Completion Date : | December 2013 |

- Overall survival (OS) [ Time Frame: Overall survival (up to 6 years) ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 30 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Clinical diagnosis of Ovarian clear cell carcinoma
Exclusion Criteria:
- not undergo operation

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02129036
Study Director: | Chih-Ming Ho | Gynecologic Cancer Center, Cathay general Hospital |
Responsible Party: | Chih-Ming Ho, Dr, Cathay General Hospital |
ClinicalTrials.gov Identifier: | NCT02129036 |
Other Study ID Numbers: |
TGOG-127 |
First Posted: | May 2, 2014 Key Record Dates |
Last Update Posted: | August 9, 2019 |
Last Verified: | April 2014 |
Ovarian cancer Clear cell carcinoma Paclitaxel-platinum Chemotherapy |
response to chemotherapy survival of clear cell ovarian carcinoma Prognostic factors |
Adenocarcinoma Adenocarcinoma, Clear Cell Ovarian Cysts Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type |
Neoplasms Cysts Ovarian Diseases Adnexal Diseases Gonadal Disorders Endocrine System Diseases |